| mRNA |
navitoclax:sorafenib (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
2e-08 |
| mRNA |
ABT-263 |
CTRPv2 |
pan-cancer |
AAC |
0.19 |
8e-08 |
| mRNA |
decitabine:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.17 |
9e-08 |
| mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
1e-07 |
| mRNA |
Cetuximab |
GDSC1000 |
pan-cancer |
AAC |
-0.18 |
1e-07 |
| mRNA |
Dasatinib |
CTRPv2 |
pan-cancer |
AAC |
-0.19 |
2e-07 |
| mRNA |
navitoclax:MST-312 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
6e-07 |
| mRNA |
navitoclax:PLX-4032 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
7e-07 |
| mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
1e-06 |
| mRNA |
Docetaxel |
GDSC1000 |
pan-cancer |
AAC |
-0.16 |
1e-06 |